Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Markets Earnings Roundup: Astra Zeneca and Teva (Part 6)

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca reports 21% growth in China, representing $72 million of the $154 million sales increase in emerging markets; and Teva reports $1.47 billion loss due to at-risk launches.

You may also be interested in...

Generic Copaxone Looms; Teva Fights And Prepares For Next Chapter

An appeals court ruling on July 26 favoring a faster route to a generic Copaxone brings to the fore longstanding issues of what its regulatory path might look like and how Teva will cope with the erosion of its top product’s sales.

Deals Of The Week: Tellingly, Teva And Lonza Part Ways

Teva and Lonza agree to dissolve their four-year-old biosimilars joint venture, created at a time when the biosimilars opportunity seemed huge, if vague. In an otherwise slow deal-making week, next-generation antibody platform company Adimab forged two transforming deals with GSK and Biogen, while Kolltan and the Children’s Hospital of Philadelphia plunged into neuroblastoma.

Affymax’s Omontys Recalled After Deaths; Uncertain Future Ahead For Company

Affymax and its partner Takeda recalled all of their ESA product after rare but unexplained patient fatalities, leaving both the product’s and the company’s future in limbo. The safety concerns may fuel fears about the unknowns of biologic production.


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts